Phys · endocrine
Disorders OF Sodium AND Water Homeostasis
Also known as Disorders OF Sodium AND Water Homeostasis · disorders of sodium and water homeostasis
Consultant-physician depth guide to Disorders OF Sodium AND Water Homeostasis for FRACP DWE/DCE preparation — presentation, differentials, investigations, management, complications and exam angles.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Missed urgency or delayed escalation in Disorders OF Sodium AND Water Homeostasis turns a salvageable presentation into preventable harm
- Treating the label without confirming the mechanism leads to wrong therapy in Disorders OF Sodium AND Water Homeostasis
- Ignoring multimorbidity and drug interactions while managing Disorders OF Sodium AND Water Homeostasis is a classic exam and clinical trap
- Failing to document the shared plan and safety-net advice after Disorders OF Sodium AND Water Homeostasis loses follow-through
- Using recalled thresholds without a cited source is forbidden — verify before acting
The answer first
Disorders of sodium and water homeostasis turn a deranged serum sodium into a decisive bedside pathway: confirm true hyponatraemia or hypernatraemia, judge the time-course and symptom severity, classify the tonicity and volume status, and commit to a therapy whose rate of correction is as important as the agent chosen.[1]
The single most dangerous error is treating a number rather than a mechanism — administering hypotonic fluids to a hypervolaemic patient, or aggressive isotonic saline to a euvolaemic SIADH patient. The 8 to 10 mmol/L per 24 hours correction limit in chronic hyponatraemia is the cardinal safety endpoint, because exceeding it causes osmotic demyelination.[1][6]
References12ShowHide
- [1]Spasovski G, Vanholder R, Allolio B, Annane D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia Eur J Endocrinol, 2014.PMID 24569125
- [2]Berl T The Adrogue-Madias formula revisited Clin J Am Soc Nephrol, 2007.PMID 17928464
- [3]Schrier RW, Gross P, Gheorghiade M, Berl T, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med, 2006.PMID 17105757
- [4]Berl T, Quittnat-Pelletier F, Verbalis JG, Bichet DG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia J Am Soc Nephrol, 2010.PMID 20185637
- [5]Rondon-Berrios H, Sterns RH Hypertonic Saline for Hyponatremia: Meeting Goals and Avoiding Harm Am J Kidney Dis, 2022.PMID 34508830
- [6]Tandukar S, Sterns RH, Rondon-Berrios H Osmotic Demyelination Syndrome following Correction of Hyponatremia by ≤10 mEq/L per Day Kidney360, 2021.PMID 35373113
- [7]Yee AH, Burns JD, Wijdicks EF Cerebral salt wasting: pathophysiology, diagnosis, and treatment Neurosurg Clin N Am, 2010.PMID 20380974
- [8]Cui H, He G, Yang S, et al. Inappropriate Antidiuretic Hormone Secretion and Cerebral Salt-Wasting Syndromes in Neurological Patients Front Neurosci, 2019.PMID 31780881
- [9]Flynn K, Hatfield J, Brown K, et al. Central and nephrogenic diabetes insipidus: updates on diagnosis and management Front Endocrinol (Lausanne), 2024.PMID 39845881
- [10]Christ-Crain M, Gaisl O Diabetes insipidus Presse Med, 2021.PMID 34718110
- [11]Kortenoeven ML, Sinke AP, Hadrup N, et al. Demeclocycline attenuates hyponatremia by reducing aquaporin-2 expression in the renal inner medulla Am J Physiol Renal Physiol, 2013.PMID 24154696
- [12]Chander S, Kumari R, Lohana AC, et al. Urea to Treat Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Systematic Review and Meta-Analysis Am J Kidney Dis, 2025.PMID 39362395